Related Experiment Video
Updated: Aug 30, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Menopausal hormone therapy and cardiovascular protection: state of the data 2003
1Emory University School of Medicine, Atlanta, Georgia, USA.
Insights
Menopausal hormone therapy does not prevent cardiovascular events and may increase risks. Focus on proven heart health strategies like diet, exercise, and smoking cessation for women.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Women's Health
Background:
- Estrogen therapy has biologically plausible mechanisms for cardiac protection.
- Observational studies suggested cardiovascular benefits of hormone therapy.
Purpose of the Study:
- To evaluate the cardiovascular outcomes of menopausal hormone therapy in randomized clinical trials.
- To assess the risks and benefits of hormone therapy for primary and secondary cardiovascular prevention.
Main Methods:
- Analysis of well-designed and conducted primary and secondary prevention randomized clinical trials.
- Review of clinical trial data on menopausal hormone therapy and cardiovascular events.
Main Results:
- Menopausal hormone therapy failed to prevent clinical cardiovascular events in healthy women and those with coronary heart disease.
- Hormone therapy increased the risk of coronary heart disease events, myocardial infarction, stroke, and venous thromboembolism.
- Increased risk of breast cancer was also observed with hormone therapy.
Conclusions:
- The harms of menopausal hormone therapy likely outweigh the benefits for most women in chronic disease prevention.
- Proven coronary risk reduction strategies include smoking cessation, healthy diet, physical activity, weight management, and managing hypertension and hypercholesterolemia.
Abstract:
Despite biologically plausible mechanisms for cardiac protection from estrogen therapy and observational data suggesting that hormone therapy confers cardiovascular benefit, the outcomes of well-designed and conducted primary and secondary prevention randomized clinical trials have documented cardiovascular risk rather than benefit. Menopausal hormone therapy failed to prevent clinical cardiovascular events in healthy menopausal women and in those with established coronary heart disease. Rather, it increased the risk of coronary heart disease events, particularly myocardial infarction, stroke, and venous thromboembolism, as well as that of breast cancer. Recommendations from the US Preventive Services Task Force emphasize that, for most women, the harms of hormone use are likely to exceed the benefits for the prevention of chronic disease. Women should talk with their health care providers about such proved approaches to coronary risk reduction as smoking cessation, heart-healthy diet, physical activity, weight management, and pharmacologic control of hypertension and hypercholesterolemia.
Related Concept Videos
Hormonal Regulation of Blood Pressure
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Menopause
Peripheral Artery Disease III: Interprofessional Care
